What is Harm Reduction?

The term “harm reduction” is gaining traction among those involved in the fight against opioid and alcohol addiction.

So, what is it exactly?

Definition Harm Reduction in Treatment | Examples

Harm Reduction Definition

“Harm reduction refers to policies, programs and practices that aim primarily to reduce the adverse health, social and economic consequences of the use of legal and illegal drugs without necessarily reducing drug consumption.”

International Harm Reduction Association

Harm reduction acknowledges that the world is not drug-free and if people are going to use drugs, then it’s better to use them in a safer environment in order to minimize the number of overdose deaths that occur. 

Methadone clinics (like Symetria) are usually considered harm reduction because methadone overdose is possible when mixed with other drugs, though around 10x less likely than other opioids. 

Goals of Harm Reduction

Harm Reduction in Treatment

Healthcare providers that use a harm reduction model meet patients where they are and encourage them to be as healthy as possible. The tone is non-judgmental and non-coercive.

Even if a patient doesn’t follow the recommended treatment plan, providers teach them skills to:

The ultimate goal of harm reduction practice is to empower individuals who misuse substances to make their own decisions and define recovery in their own terms. This approach values collaboration between provider and patient.

6 Principles of Harm Reduction in Treatment

Applying these six principles of harm reduction helps improve the quality of the provider-patient relationship, which may also improve clinical care outcomes and treatment adherence.

Harm Reduction Examples

Harm reduction can be a specific initiative, but it can also be a mindset to how people struggling with substances are treated — by society, within the laws, by law enforcement, by families or by healthcare professionals, for example.

Harm Reduction Advice

Harm Reduction Programs

Harm reduction began as a grass-roots movement in the 1980s during the HIV crisis. It started with needle exchange programs to ensure that if someone was injecting drugs, such as heroin, they were doing it safely and not spreading the disease. 

Today, organized harm reduction groups still provide needle exchanges as well as safe injection sites which go a step further to provide 24/7 supervision and connection to mental health resources. 

Additionally, harm reduction groups like The Harm Reduction Coalition (HRC) advocate for the decriminalization of drugs and for Good Samaritan laws that offer legal protection to those seeking medical care for themselves or others during an overdose. 

Another important initiative of harm reduction groups is to distribute and educate on how to use naloxone, the anti-overdose drug. Naloxone (Narcan) training can be geared toward families of those using, the general public, healthcare providers or police forces. 

Medication-Assisted Treatment (MAT) programs that include the use of Suboxone or methadone are also considered harm reduction in contrast to the traditional abstinence-only programs. 

Getting Harm Reduction Treatment

"If treatment is on a linear continuum with abstinence-based and harm reduction on opposite ends, Symetria is much close to the harm reduction side. The goal here is to help patients stop using as soon as possible. However, we don't kick someone out of treatment for lapsing, even multiple times. We let patients drive their own treatment. Working together with care and respect and on a patient-by-patient basis to help them meet the goals they set for themselves."

Masroor Ahmed, CEO

Harm Reduction Addiction Treatment

Still Have Questions?

Subscribe
Notify of
guest

0 Comments
Inline Feedbacks
View all comments

Symetria doctors follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and their own expertise with decades in the field.

American Society of Addiction Medicine (ASAM). (2020). National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2

Axelrod, S. R. (2019). Dialectical behaviour therapy for substance use disorders. In M. A. Swales (Ed.), The Oxford handbook of dialectical behaviour therapy (p. 595–614). Oxford University Press

Behar, E., Bagnulo, R., Knight, K., Santos, G., Coffin, P. O. (2020). “Chasing the pain relief, not the high”: Experiences managing pain after opioid reductions among patients with HIV and a history of substance use. PLoS One, 15(3), 1-16. https://doi.org/10.1371/journal.pone.0230408

Bruneau, J., Ahamad, K., Goyer, M. E., Poulin, G., Selby, P., Fischer, B., Wild, T. C., & Wood, E. (2018). Management of opioid use disorders: a national clinical practice guideline. CMAJ, 190(9), 247-257. https://doi.org/10.1503/cmaj.170958

Carson, L. (2019). Stigma associated with opioid use disorders in adolescents limits naloxone prescribing. Journal of Pediatric Nursing, 49, 92-96. https://doi.org/10.1016/j.pedn.2019.10.005

Cicero, T. J., Ellis, M. S., & Kasper, Z. A. (2020). Polysubstance Use: A Broader Understanding of Substance Use During the Opioid Crisis. American Journal of Public Health, 110(2), 244–250. https://doi.org/10.2105/AJPH.2019.305412

Dorsey, K. (2020). Supervised injection facilities and harm prevention in recreational drug users. Physician’s Assistant Program Capstones, 54. https://scholarlycommons.pacific.edu/pa-capstones/54

Eggleston, W., Calleo, V., & Kim, M. (2020). Naloxone administration by untrained community members. Pharmacotherapy, 40(1), 84-88. https://doi.org/10.1002/phar.2352

Evans, T. I., Hadland, S. E., Clark, M. A., Green, T. C., & Marshall, B. D. (2016). Factors associated with knowledge of a Good Samaritan Law among young adults who use prescription opioids non-medically. Harm reduction journal, 13(1), 24. https://doi.org/10.1186/s12954-016-0113-2

Faghir-Gangi, M., Rastad, H., Nejat, S., Rahimi-Movaghar, A., Yazdani, K., & Mirzazadeh, A. (2020). Understanding the reasons for sharing syringes or needles to inject drugs: conventional content analysis. Addiction & Health, 12(2), 98-108. https://doi.org/10.22122/ahj.v12i2.255

Garland, E. L., Baker, A. K., Riquino, M. R., Priddy, S. E. (2020). Mindfulness-oriented recovery enhancement. In I. Ivtzan (Ed.), Handbook of Mindfulness-Based Programmes: Mindfulness Interventions from Education to Health and Therapy. (n.p.). Routledge.

Goodyear, T., Mniszak, C., Jenkins, E., Fast, D., & Knight, R. (2020). “Am I gonna get in trouble for acknowledging my will to be safe?”: Identifying the experiences of young sexual minority men and substance use in the context of an opioid overdose crisis. Harm Reduction Journal, 17(1), 1–14. https://doi.org/10.1186/s12954-020-00365-4

Hanson, B. L., Porter, R. R., Zold, A. L., & Terhorst-Miller, H. (2020). Preventing opioid overdose with peer-administered naloxone: findings from a rural state. Harm Reduction Journal, 17, Artile 4. https://doi.org/10.1186/s12954-019-0352-0

Harm Reduction Coalition. (2018). The Principles of Harm Reduction. http://harmreduction.org/about-us/principles-of-harm-reduction/
Harm Reduction International. (2021). What is harm reduction? https://www.hri.global/what-is-harm-reduction

Hawk, M., Coulter, R. W. S., Egan, J. E., Fisk, S. Friedman, M. R., Tula, M. & Kinsky, S. (2017). Harm reduction principles for healthcare settings. Harm Reduction Journal, 14, Article 70. https://doi.org/10.1186/s12954-017-0196-4

Kerr, J., Atlas, M., Crabtree, W., Chen, Y.-T., & Moyer, S. (2019). Examining Social-Ecological Factors in Developing the Louisville Metro Department of Public Health and Wellness Syringe Exchange Program. American Journal of Public Health, 109(3), 454–457. https://doi.org/10.2105/AJPH.2018.304897

Liu, T., Shi, J., Epstein, D. H., Bao, Y-P., & Lu, Lin. (2009). A meta-analysis of acupuncture combined with opioid receptor agonists for treatment of opiate-withdrawal symptoms. Cellular and Molecular Neurobiology, 29: 449-454.

Office of the Surgeon General. (2018). U.S. Surgeon General’s advisory on naloxone and opioid overdose. U.S. Department of Health & Human Services. https://www.hhs.gov/surgeongeneral/priorities/opioids-and-addiction/naloxone-advisory/index.html

Raihan, N. & Cogburn, M. (2020). Stage of Change Theory. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK556005/

Spas, J. J., Buscemi, J., Prasad, R., Janke, E. A., & Nigg, C. R. (2020). The Society of Behavioral Medicine supports an increase in funding for Medication-Assisted-Treatment (MAT) to address the opioid crisis. Translational Behavioral Medicine, 10(2), 486–488. https://doi.org/10.1093/tbm/ibz004

Spaulding, S. D. & Canady, B. E. (2020). Barriers to needle return in harm reduction programs. Professional Psychology: Research and Practice, 51(1), 10-15. http://dx.doi.org/10.1037/pro0000263

Strayer, R.J., Hawk, K., Hayes, B.D., Herring, A.A., Ketcham, E., LaPietra, A.M., Lynch, J.J., Motov, S., Repanshek, Z., Weiner, S.G., & Nelson, L.S. (2019). Management of Opioid Use Disorder in the Emergency Department: A White Paper Prepared for the American Academy of Emergency Medicine. American Academy of Emergency Medicine. https://www.aaem.org/UserFiles/file/AAEMOUDWhitePaperManuscript.pdf

Stopka, T. J., Donahue, A., Hutchenson, M., Green, T. C. (2017). Nonprescription Naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts. Journal of the American Pharmacists Association, 57, S34-S44.

Strike, C., & Miskovic, M. (2018). Scoping out the literature on mobile needle and syringe programs – Review of service delivery and client characteristics operation, utilization, referrals, and impact. Harm Reduction Journal, 15, 6.

Strike, C., & Watson, T. M. (2017). Relationships between needle and syringe programs and police: An exploratory analysis of the potential role of in-service training. Drug and Alcohol Dependence, 175, 51-54.

Substance Abuse and Mental Health Services Administration (SAMHSA). (2018). Treatment Improvement Protocol (TIP) Series, no. 63. Chapter 3A: Overview of Pharmacotherapy for Opioid Use Disorder. https://www.ncbi.nlm.nih.gov/books/NBK535278/

Substance Abuse and Mental Health Services Administration. (2019). Treatment Improvement Protocol 35: Enhancing Motivation for change in substance use disorder treatment. https://store.samhsa.gov/sites/default/files/d7/priv/tip35_final_508_compliant_-_02252020_0.pdf

Taylor, E., Timko, C., Harris, A.H.S., Yu, M., & Finlay, A.K. (2019). Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration. Addiction Science & Clinical Practice, 14(1). 1. https://doi.org/10.1186/s13722-018-0129-x

Vakharia, S. P. & Little, J. (2017). Starting where the client is: Harm reduction guidelines for clinical social work practice. Clinical Social Work Journal, 45, 65-76. https://doi.org/10.1007/s10615-016-0584-3

Disclaimer
All content is for informational purposes only. No material on this site, whether from our doctors or the community, is a substitute for seeking personalized professional medical advice, diagnosis or treatment. Never disregard advice from a qualified healthcare professional or delay seeking advice because of something you read on this website.

Symetria has addiction treatment clinics across Illinois and Texas. You can likely get scheduled TODAY — medications or therapy. 

Hi there — Most people want to know costs/insurance upfront. Would you like to check your policy now?